P elvic inflammatory disease (PID) is an infection of the upper female reproductive tract. 1 This serious but treatable infection can lead to complications such as ectopic pregnancy, tubal factor infertility, and chronic pelvic pain. 2 Although the rates of PID have decreased over the past decade in the United States, it still represents a significant health problem among women of reproductive age. 3 Among the US Army women, PID is also commonly diagnosed, with an estimated rate of approximately 11 PID cases per 1000 person-years from 2002 to 2011. 4 Chlamydia trachomatis infection is an important risk factor for the development of PID, but its risk varies considerably. 5 For example, Hillis et al. 6 reported that the odds ratios of PID were 4.0 and 6.4 among 11,000 Wisconsin women with 2 versus 3 or more chlamydia infections, respectively. In contrast, Davies et al. 7 recently reported that among Canadian women, the risk of PID after the first and the second repeat chlamydia infections was 1.2 and 1.3 compared with those with 1 infection, respectively. A plausible explanation for these differences may be due to the clinical diagnosis of PID being imprecise and a challenge, without a gold standard diagnostic test. 1, 8 Since 2000, the US Army has reported that chlamydia is the most commonly diagnosed bacterial sexually transmitted infection (STI). 9 However, the risk of PID after having repeated chlamydia infections has not been studied to date. Therefore, the aim of this study was to determine the relationship between the number of chlamydia diagnoses and hazard of PID among female military personnel. To reach that aim, we conducted a retrospective cohort analysis using data from the Defense Medical Surveillance System (DMSS). 10 
METHODS

Study Design and Population
Data were extracted from the DMSS, a large relational database that serves as the medical surveillance system for the US Armed Forces since the 1990s. 10 The DMSS collects information on demographics, medical encounters, immunizations, laboratory results, and deployments among personnel from the first day of entry until their departure from service. The study population included all US Army women aged 17 to 40 years, who were on active duty for any time frame between January 1, 2006, and December 31, 2012, and who had at least one chlamydia diagnosis while in service. The "chlamydia case" definition was based on the International Classification of Diseases, Ninth Version (ICD-9) diagnostic codes 099.41 or 099.5x in either the first or second position of an inpatient or outpatient medical record. Women with a diagnosis of chlamydia, PID (614.9), infertility (628.4), pregnancy (V22.2), or gonorrhea (098.0x, 098.1x, or 098.8x) before January 1, 2006 were excluded. Pregnant women were excluded to ensure homogeneity in terms of sexual risk in our population because risky behavior would probably be minimized during pregnancy by female service members in accordance with medical advice.
Consequently, medical encounter records from all chlamydia cases were reviewed to determine the number of repeat chlamydia diagnoses (e.g., "repeaters") since the first date of diagnosis until they reached one of the following censoring events: (1) a diagnosis of PID (list of ICD-9 codes is shown as a footnote in Table 2 ), (2) end of the study period, or (3) termination of service. A repeat chlamydia diagnosis was defined as a diagnosis that occurred at least 30 days from a prior positive chlamydia test. Although this time frame varies from study to study, a period of 30 days has been most often used in epidemiologic assessments to avoid duplication of diagnosis for a single episode. 11, 12 Besides, it is based on the evidence that nucleic acid amplification testing can detect residual C. trachomatis nucleic acid for up to 3 weeks after treatment 13 and follows the US Centers for Disease Control and Prevention guidelines to report a positive chlamydia laboratory as a new infection. 14 In addition to reviewing medical encounter data, for each chlamydia case detected during the study period, we extracted data from the DMSS with respect to sociodemographic and military specific variables. These variables included (1) age (in years), (2) race/ ethnicity (white, African American, Hispanic, and other), (3) education (high school, college or higher), (4) marital status (single, married, and other), and (5) military rank (officer, enlisted).
Statistical Analysis
The demographic characteristics of the study population were summarized using descriptive statistics (e.g., means for continuous data and frequencies for categorical data). We used the Kaplan-Meier estimator to determine the cumulative incidence rate of PID by the end of follow-up after the first, second, and third time repeaters. To compare Kaplan-Meier cumulative incidence curves of PID diagnosis, the log-rank test was used. We applied a Cox proportional hazards regression model to study differences on the distribution of time to PID diagnosis by the number of repeat chlamydia diagnoses. The proportional hazards assumption was evaluated using the Schoenfeld global test. 15 Because of the small number of women with more than 3 repeat chlamydia diagnoses during the study period, these were excluded from analysis. Data were analyzed using Stata version 12 (Stata Corporation, College Station, TX).
RESULTS
The study population comprised 33,176 female military personnel with a chlamydia diagnosis during the period 2006-2012. Of these, the mean (SD) age at initial chlamydia diagnosis was 21.9 (3.7) years and the median follow-up time was 2.9 (interquartile range, 1.5-4.7) years. As shown in Table 1 , 25,098 (75%) women were diagnosed as having C. trachomatis only once ("nonrepeaters"). By comparison, 6282 (19%), 1435 (4%), and 361 (1%) women had one, two and three repeat chlamydia diagnoses, respectively. Among the repeaters, highest burden was in women aged 20 to 24 years (52%-53%), African Americans (37%-44%), those of single marital status (73%-78%), those with high school education (93%-97%), and those within the enlisted ranks (91%-95%).
Among the 33,176 women, a total of 1533 (5%) PID diagnoses were subsequently diagnosed with a median time to diagnosis of nine months. Results stratified by repeat chlamydia diagnosis (Table 2) indicate that among the 25,098 women without a repeat chlamydia diagnosis, there were 1111 (4%) PID diagnoses. In this "nonrepeater" group, the median time to PID diagnosis was 13 months. For "repeater" women with one repeat chlamydia diagnosis, 325 (5%) of 6282 had a diagnosis of PID, with a median time of 10 months. For women with two repeat chlamydia diagnoses, 72 (5%) of 1435 had a diagnosis of PID, with a median time to diagnosis of 8 months. In addition, for 361 women with three (14) 3780 (15) 598 (9) 84 (6) 19 (5) repeat chlamydia diagnoses, there were 25 (7%) PID diagnoses, with a median time to diagnosis of only one month. According to the Kaplan-Meier analysis, the cumulative incidence of PID increased in a dose-response relationship among chlamydia repeaters, from 6% for women with a single chlamydia diagnosis (nonrepeaters) to 9%, 10%, and 11% for women with one, two and three repeat chlamydia diagnoses, respectively ( Table 2) . The relationship between the 4 study groups and cumulative incidence proportion of PID (1-survival) is depicted in Figure 1 . Clearly, we can observe that as the number of chlamydia diagnoses increased, the incidence of PID increased. In addition, the results showed that cumulative risk curves were statistically significantly different by the log-rank test (P < 0.001).
According to the Cox regression analysis, for every additional diagnosis of chlamydia, the hazard of PID increased by 28% (95% confidence interval [CI], 19%-38%; P < 0.001) compared with women with a single diagnosis or nonrepeaters. After controlling for age in years, race/ethnicity, marital status, and military rank, the hazard for PID decreased to 22% (95% CI, 13%-32%; P < 0.001) per additional chlamydia diagnosis, but remained statistically significant. When the number of repeat chlamydia diagnoses was treated as a categorical predictor, as shown in Table 2 , analysis revealed that women with one (hazard ratio [HR], 1.34), 2 (HR, 1.48), and 3 (HR, 2.21) repeat chlamydia diagnoses were at a significantly greater hazard of a diagnosis of PID as compared with women with a single diagnosis. Moreover, after controlling for the previously mentioned potential confounders, the adjusted HRs showed significantly greater risk for PID among the three repeater groups compared with nonrepeaters. On the basis of the Schoenfeld global test, the proportional hazards assumption was met in both univariate (P = 0.338) and multivariate (P = 0.176) analyses.
DISCUSSION
In this retrospective cohort analysis of 33,176 US Army women, we found that the hazard of PID increased in a doseresponse relationship with each additional repeat chlamydia diagnosis. This finding highlights the importance of repeat chlamydia as a predisposing factor for the development of subsequent PID and associated morbidity. Furthermore, our findings are consistent with previous studies conducted among civilian populations. 6, 7, 16, 17 The characteristics of the study population were consistent with those reported in other military-based studies in the literature. 9, 11 That is, among US Army women, most chlamydia diagnoses occur among those aged 17 to 24 years, African Americans, single, and in junior enlisted military ranks. In our study, the percentage of women with repeat chlamydia diagnosis (24%) was slightly higher than that estimated by Owings et al., 12 who reported that between 2010 and 2014, 20% of 23,482 female service members in the US military were chlamydia repeaters. Nonetheless, this difference may be due to differences in periods. According to military surveillance reports, there was a peak in the annual incidence rate for chlamydia in 2008. 18 Our results also showed that the median time in months to PID diagnosis decreased by the number of chlamydia diagnoses. Although this finding may have important public health implications in terms of screening, it is worth mentioning that using administrative health data like the DMSS, it is difficult to estimate exactly the time from chlamydia infection to PID diagnosis because both the exposure and outcome are highly asymptomatic. With this caveat in mind, our data suggest that it may be wise to reinforce primary prevention activities as counseling and education to prevent a subsequent PID diagnosis among chlamydia repeaters among US Army women.
To the best of our knowledge, this is the first study to report the cumulative effect of repeat chlamydia diagnosis on the hazard of PID in the US military, a young, highly mobile, and sexually active population. 19 According to DMSS data, the risk of PID for every one additional diagnosis of chlamydia increased by 28%, although this percentage was attenuated, but remained high (22%) when adjusted for demographic and military characteristics. Although this was an observational study, we are not able to clearly explain the reasons for the increased risk or demonstrate a causal relationship between repeat chlamydia and PID diagnosis. However, we provide additional evidence on the impact of repeat chlamydia diagnoses on the risk of PID to the STI literature. In addition to the observed cumulative effect of repeat chlamydia on PID, we found that the hazard of PID increases with the number of diagnoses of chlamydia. Although our hazard estimates cannot be directly compared with previous civilian studies because they vary in terms of methodology, study population, and case identification, [6] [7] [8] 16, 17, 20 the consensus is the same. In other words, there is an increasing risk of PID after repeat chlamydia diagnoses. Despite these differences, the adjusted HRs of PID were similar to those reported by the largest published cohort of chlamydia and PID conducted to-date. 7 In that study, conducted in Canada among 73,883 women aged 12 to 24 years during the period 1992-1996, the risk of PID after one and two repeat chlamydia diagnoses was 17% (95% CI, 6%-30%) and 35% (95% CI, 4%-75%), respectively.
Limitations
This study has some limitations. First, the DMSS does not collect data on vaginal sanitary practices (e.g., douching), risky sexual behaviors (e.g., multiple risk partners), or use of oral or other forms of contraception. Therefore, unmeasured confounders can affect the accuracy of our estimates. Second, PID and chlamydia are often asymptomatic; therefore, the reported rates of PID might be underestimated and the number of women with repeat chlamydia diagnoses might be higher than analyzed. Besides, a long-term asymptomatic chlamydia infection increases the likelihood of developing PID compared with those that are diagnosed and treated quickly. Third, the most widely used ICD-9 code (614.9) was applied to identify PID; however, some PID diagnoses might have been missed if a clinical diagnosis of PID was represented by other ICD-9 codes. This may have resulted in an underestimation of the total number of PID cases in our study population. Finally, the length of follow-up in our study (a median of 3 years) may not have captured all PID cases (e.g., PID could have occurred after the study period ended). Therefore, this could have resulted in an underestimation of the true incidence of PID. However, its effect is difficult to judge because each year approximately 10,000 new women enter and leave the US Army. 21 Notwithstanding our limitations, this study included a large number of women, which increases the statistical precision of the parameter estimates. Furthermore, all eligible female service members with a chlamydia diagnosis during the study period were selected; thus, the risk of selection bias was minimized. Also, this is the first investigation reporting the time intervals between repeat chlamydia diagnoses and a subsequent diagnosis of PID, as well as the cumulative effect of repeat chlamydia on PID. With the data presented, we feel that our findings contribute with objective, diagnosis-based, measurable evidence on the role that chlamydia plays as a risk factor for PID.
In conclusion, this study suggests that the hazard of a diagnosis of PID increased significantly with the number of repeat chlamydia diagnoses among US Army women, and this relationship was found to be characterized by a dose-response. Additional research is needed to better understand the reasons for this increased risk for subsequent PID diagnosis. These findings reinforce the notion that early diagnosis and treatment of chlamydia is necessary to avoid subsequent PID and associated morbidity. It may be wise for military medical policy makers to consider developing new preventive strategies that are effective in reducing the risk of PID among chlamydia repeaters, a targeted subgroup for further STI research in the US Army.
